UPC APP 67755/2024
EP4026488 Unitary patent · TRANSCUTANEOUS ANALYTE SENSOR SYSTEMS AND METHODS
- Case details
- StatusWithdrawnActionProcedural applicationCategoryWithdrawal applications
- Parties
- Claimants
- Dexcom Inc.Operating co.
Representatives- Markus Grosch-Quinn Emanuel Urquhart & Sullivan LLP
- Johannes Bukow-Quinn Emanuel Urquhart & Sullivan LLP
- Jan Axtmann-Quinn Emanuel Urquhart & Sullivan LLP
- Paul Lehmann-Quinn Emanuel Urquhart & Sullivan LLP
Respondents- Abbott LaboratoriesOperating co.
- Abbott Diabetes Care Inc.Operating co.
- Abbott GmbHOperating co.
- Abbott Diagnostics GmbHOperating co.
- Abbott Laboratories GmbHOperating co.
- Abbott Logistics B.V.Operating co.
- Abbott FranceOperating co.
- Abbott s.r.l.Operating co.
- Abbott Gesellschaft m.b.H.Operating co.
- Abbott B.V.Operating co.
- Abbott (S.A./N.V.)Operating co.
- Abbott Scandinavia AktiebolagOperating co.
- Abbott OyOperating co.
Representatives- Dietrich Kamlah-Taylor Wessing
- Christian Lederer-Taylor Wessing
- Gisbert Hohagen-Taylor Wessing
- Division
- Dusseldorf LD
- Technology
- InstrumentsMedical technology
- Language
- —
- First decided
- Jan 7, 2025
- EPO Opposition
- Abbott Diabetes Care Inc.Withdrawn2024-04-18
- Abbott GmbHWithdrawn2024-04-19
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Dusseldorf LD | Locked |
| Judge Ronny Thomas | Locked |
| Judge Berenice Thom | Locked |
| Judge Petri Rinkinen | Locked |
| Judge Claus Elmeros | Locked |
At the UPC: Dexcom Group (39 cases)·Abbott Group (67 cases)
This dispute contains 3 other proceedings
Start a free trial to see how each one ended.
More cases: Dusseldorf LD·2024
- 2025-01-07Application RoP 265Public
Summary: Düsseldorf Local Division decision allowing the withdrawal of DexCom's infringement action (including application to amend the patent) and Abbott's counterclaim for revocation by mutual consent (R. 265 RoP). Following an out-of-court settlement, DexCom agreed to withdraw the infringement action and Abbott agreed to withdraw the revocation counterclaim. Neither party requested a costs decision. The oral hearing scheduled for 8 May 2025 was cancelled. Court fees reimbursed: DexCom receives 60% of infringement action fees (EUR 22,200), Abbott receives 60% of revocation counterclaim fees (EUR 12,000).
Show the legal issues (3)
- Withdrawal of action by mutual consent (R. 265 RoP)
- Settlement
- Court fee reimbursement (R. 370.11, R. 370.9(b)(i) RoP)
- D643D8A1AE51F166070DD5D184A0BBB5_en.pdf2025-01-07EN